1-9 of 9
F. Zafar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin B. Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Rocco J. Crescenzo, Kunthel By, Aileen Cleary Cohen, Adam Idoine, Sudhir Manda, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6510.
https://doi.org/10.1182/blood-2023-180161
Published: 2023
Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Linlin Xu, Mazyar Shadman, Anusha Ponakala, Ian W. Flinn, Moshe Yair Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Aileen Cohen, Dih-Yih Chen, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9269–9271.
https://doi.org/10.1182/blood-2022-167758
Published: 2022
Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Jennifer L. Cultrera, Jamal Misleh, Syed F. Zafar, Benjamin Freeman, Subramanya S. Rao, Habte Yimer, Arvind Chaudhry, Mitul D. Gandhi, Troy H. Guthrie, Edwin Kingsley, Praveen K. Tumula, Sudhir Manda, Dih-Yih Chen, Aileen Cohen, Kunthel By, Linlin Xu, Ye Liu, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1410.
https://doi.org/10.1182/blood-2021-148544
Published: 2021
Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Ryan Jacobs, Wojciech Jurczak, Ian W. Flinn, Sebastian Grosicki, Krzysztof Giannopoulos, Tomasz Wróbel, Syed F. Zafar, Jennifer L. Cultrera, Suman Kambhampati, Alexey V. Danilov, John M. Burke, Jerome Goldschmidt, Douglas F. Beach, Scott F. Huntington, Javier Pinilla Ibarz, Jeff P. Sharman, Tanya Siddiqi, Danielle M. Brander, Mazyar Shadman, John M. Pagel, Monika Dlugosz-Danecka, Nilanjan Ghosh, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Owen A. O'Connor, Michael S. Weiss, John G. Gribben
Journal: Blood
Blood (2021) 138 (Supplement 1): 3726.
https://doi.org/10.1182/blood-2021-147460
Published: 2021
Journal Articles

Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Javier Pinilla Ibarz, Wojciech Jurczak, Suman Kambhampati, Ewa Lech Maranda, Tomasz Wróbel, Jeff P. Sharman, Syed F. Zafar, Marc Hoffmann, Scott F. Huntington, Ryan Jacobs, Osnat Bairey, Chris Rowland, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Owen A. O'Connor, Ian W. Flinn
Journal: Blood
Blood (2021) 138 (Supplement 1): 3748.
https://doi.org/10.1182/blood-2021-151292
Published: 2021
Journal Articles

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Mazyar Shadman, MD MPH, Jeff P Sharman, MD, Moshe Y. Levy, MD, Jamal Misleh, MD, Syed F. Zafar, MD, Benjamin B. Freeman, MD, John M. Burke, MD, Jennifer L. Cultrera, MD, Habte A. Yimer, MD, Dih-Yih Chen, MD, Xiaoping Zhang, MD, Aileen Cohen, MD PhD, Sunhee Ro, PhD, Jane Huang, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-134621
Published: 2020
Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–39.
https://doi.org/10.1182/blood-2020-134783
Published: 2020
Journal Articles

Lenalidomide Induced Myelosupression Is Potentially Associated with Renal Dysfunction in Treatment Naïve Myeloma (MM) Patients Receiving BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx).

Ruben Niesvizky, MD, D.S. Jayabalan, F. Zafar, P. Christos, R. Lent, MD, R. Pearse, MD,PhD, J. Tepler, MD, S. Ely, MD, T. Shore, MD, J. Harpel, MD, PhD, M. Schuster, MD, K. Pekle, J.B. Jalbrzikowski, H.J. Cho, MD,PhD, J. Leonard, MD, M. Mazumdar, S. Chen-Kiang, PhD, M. Coleman, MD
Journal: Blood
Blood (2006) 108 (11): 3549.
https://doi.org/10.1182/blood.V108.11.3549.3549
Published: 2006
Journal Articles

BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features.

Ruben Niesvizky, MD, K. Pekle, RN, ANPC, U. Gelbshtein, F. Zafar, RPAC, S. Ostrow, MD, R. Pearse, MD, PhD, H. Cho, MD, PhD, J. Tepler, MD, S. Ely, MD, R. Lent, PhD, D. Jayabalan, T. Shore, MD, J. Harpel, MD, PhD, M. Schuster, MD, L. Lyons, R. Furman, MD, J. Leonard, MD, S. Chen-Kiang, PhD, M. Coleman, MD
Journal: Blood
Blood (2005) 106 (11): 642.
https://doi.org/10.1182/blood.V106.11.642.642
Published: 2005